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ABSTRACT 
 
Introduction: Surgical antibiotic prophylaxis (SAP) is an effective way of preventing surgical 
site infections (SSI). However the 2014 National Antimicrobial Prescribing survey (NAPS) 
conducted in St. Vincent’s Public Hospital Sydney (SVH) revealed relatively poor adherence 
to SAP guidelines, with 43% SAP administered beyond 24 hours. This study therefore aimed 
to investigate the adherence to SAP national guidelines among the SVH Orthopaedic team, 
and determine the extent to which development of local guidelines and performing face-to-
face feedback with the prescribers would improve adherence. 
 
Methods: This project was conducted as a pre-post intervention study carried out in three 
phases. In Phase 1, SAP prescribing patterns (antibiotic choice, dose, timing and duration) 
were audited retrospectively using a drug-use evaluation instrument. Results were compared 
to the national Therapeutic Guidelines (Antibiotic) version 14 for appropriateness of 
prescribing. In Phase 2, an educational intervention was undertaken which included audit 
results presentation to prescribers and distribution of in-hospital guidelines developed by the 
Antimicrobial Stewardship. In Phase 3, a second round of data was collected using same 
instrument, in order to identify any changes in prescribing. 
 
Results: The intervention combination produced positive results in improving the 
Orthopaedic team’s adherence rates. The overall adherence rate increased significantly from 
32.2% to 56.1% (p<0.05). All parameters apart from duration improved; increase in 
adherence to drug dosing was the most outstanding in terms of relative rise. Relatively junior 
physicians and surgeons with average performances showed greatest improvement in 
adherence to SAP guidelines after the educational intervention.  
 
Conclusions: Quality of prescribing and adherence to SAP guidelines can be improved 
through the use of peer feedback with an opportunity for prescriber reflection and by the 
development and disseminating local guidelines. 
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CHAPTER 1: INTRODUCTION 
 
Surgical site infections are undesired outcomes following an operative procedure, 
which can be avoided by the administration of suitable antibiotic prophylaxis. However the 
use of antibiotic prophylaxis was far from ideal, according to studies conducted worldwide. 
Multiple interventions have been suggested in order to improve physicians’ awareness to 
antibiotic administrations recommended by guidelines.  
 
1.1 Surgical antibiotic prophylaxis 
 
Surgical site infections (SSIs) are defined as infections caused by an operative 
procedure; SSIs must occur within 30 days of procedure, or up to 1 year after surgery if a 
prosthetic implant was inserted1. It may occur at the skin and subcutaneous tissue of the 
incision site (superficial incisional SSIs), the deep soft tissue (deep incisional SSIs) or any 
other anatomical areas of the body (organ/space SSIs.) As defined by the United States 
Centers for disease control and prevention2 (CDC), having a purulent drainage is a diagnostic 
criterion for SSIs.  
 
SSI is one of the most common hospital-acquired infections; it is also the most 
common complication of surgeries1 and second most common adverse event in hospitalised 
patients3. Not only do SSIs double mortality rates4, lead to patient suffering and poorer 
outcomes; they are also related to higher expenditures caused by longer hospital stays5 (on 
average 7 days longer), 60% higher risk of ICU admissions6, higher rates of post discharge 
infections, consumption of community-based serviced 7 , additional antibiotic treatment, 
higher chance of re-implantation and 5 times the risk of hospital readmission3.  Nonetheless, 
40-60% of SSIs are in fact preventable2,8.  
 
The Australian Therapeutic Guidelines ver 15 (TG)9 has stated that the optimal use of 
surgical antibiotic prophylaxis (SAP) has been shown to reduce the risk of both SSIs10, 11 and 
the development of bacterial resistance.  
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SAP is not aiming at sterilising the tissues for operation12, but rather to modulate the 
level of contamination of the surgical wound so that the hosts’ immune system would not be 
overwhelmed by the bacterial burden throughout the incision period13. 
 
SAP may be required in two main circumstances:  
1. Where the surgery has more than 10% risk of developing a SSI14 (i.e. clean-contaminated 
wounds); as well as  
2. Where the development of SSI, although unlikely, leads to hazardous consequences such 
as device replacement, sepsis and possibly death15.  
Orthopaedic surgeries including hip replacement, knee replacement and open reduction with 
internal fixation (ORIF) operations are examples of the second16 and thus SAP is indicated. 
Hand, foot & ankle surgeries as well as arthroscopies have a SSI rate of 1.6% and 0.2% 
respectively, thus the use of SAP is not supported12. 
 
The TG have provided clear recommendations of SAP for orthopaedic surgeries. 
International guidelines such as those of the American Society of Health-System pharmacists 
(ASHP), American Academy of Orthopedic surgeons (AAOS) and the Scottish 
Intercollegiate Guidelines Network (SIGN) have stated similar advice16.  
 
The appropriateness and effectiveness of SAP depends on the antibiotic(s) 
administered, their dose, timing and duration17. In order to cover the most common bacterial 
pathogens in orthopaedic surgeries, namely, Staphylococcus aureus and coagulase-negative 
staphylococci1; cefazolin is the preferred drug option for most patients9 as it covers the 
narrowest required spectrum18. The use of glycopeptides such as vancomycin may be suitable 
in patients with immediate penicillin hypersensitivity as well as multidrug-resistance 
Staphylococcus aureus (MRSA) carriers16. The dose of antibiotic to be usually administered 
is based on the patient’s weight; however, for some antibiotics a threshold weight in adults is 
used and a different dose nominated above and below this threshold. SAP should be given 
within 60 minutes before incision for best coverage, ideally within 15 to 30 minutes of the 
first incision9. As the patient is usually ‘nil by mouth’ prior to surgery and a rapid onset is 
required, the antibiotic is usually administered intravenously. Increased infection rates have 
resulted when the time between administration of SAP and first incision exceeds an hour19. 
Duration of surgery will also impact on the effectiveness of SAP. Current guidelines suggest 
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the use of a single dose of cefazolin for surgeries within 4 hours; no extra benefit has been 
demonstrated if SAP was prolonged beyond 24 hours after orthopedic surgeries wound 
closure9,16.  
 
1.2 The current situation 
  
Despite clear guidance on the appropriate administration of SAP, studies conducted 
worldwide have reported a high degree of non-adherence to guidelines in clinical practice. A 
large medical records review performed in China, including 14525 patients from various 
surgical areas reported a 9.4% overall adherence rate; with an adherence rate below 31% in 
drug choice, timing and duration20. A study published in 2011 and conducted in Iran noted a 
4.65% overall adherence21. A cross-sectional epidemiology study published in 2013 in Italy 
revealed overall appropriateness to be 18.1%22. A prospective study in Dutch reported an 
adherence rate of no lower than 43% in any SAP aspects; nevertheless the overall adherence 
rate was only 28% 23 . In 2007, a Korean study taking into account multiple surgical 
disciplines, reported that 99.8% of the SAPs were administered beyond 24 hours post 
operation; with an average duration of 12.3 days14.  
 
The National Antimicrobial Prescribing survey (NAPS) performed in St. Vincent’s 
Public Hospital (SVH) in 2014 has also suggested insufficient adherence to guidelines24 in 
our setting. More than 57% of SAP was administered beyond the recommended 24 hours 
post-operation.  
 
1.3 Interventions that improve appropriateness of prescribing  
 
In order to address the non-adherence to SAP guidelines among prescribers, recent 
literature has suggested numerous methods in hope of increasing adherence to SAP 
guidelines. These varied from simple measures such as pre-printed SAP forms/stickers25 and 
a reminder system for re-dosing26 to complicated solutions such as outreach programs and 
regular auditing of SAP practices17. The suggested methods included physical means such as 
change of SAP location27  to augment timing and fixed stock of antibiotics in operation 
rooms17 as well as behavioural adjustments, for example, delegation of responsibility to 
particular team members26, development of leadership28 and a safety culture26 among the 
medical team. Pharmacist involvement was suggested to be an effective means of a quality 
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improvement intervention4, 17. It was generally accepted that multiple strategies may be 
effective in improving awareness to SAP guidelines; however, it was difficult to rule out 
which interventions actually improved adherence.  
 
In order to capture the SAP adherence rates for quality assessment, drug utilisation 
evaluation (DUE) strategies have been employed and formal programs have been set up in 
hospitals throughout the world 29 . The American Society of Health-System Pharmacists 
defines a DUE program as "a structured, ongoing, organisationally authorised, quality 
assurance process designed to ensure that drugs are used appropriately, safely and 
effectively"30. This approach is an important shift of focus from input criteria designed to 
reduce medication costs to improving patient outcomes. DUE programs are more than 
clinical audit. As well as evaluating outcomes through pre-/post-audit, DUEs incorporate an 
intervention strategy to encourage positive behavior change. Strategies include educational 
interventions such as guideline development and peer feedback4. DUE programs prosper 
because they meet the needs of hospital and government administrators, hospital pharmacists 
and other health professionals as well as the patient. Their continued success is however 
greatly enhanced by a strong and well accepted clinical pharmacy service within the hospital. 
 
1.4 Aim 
 
This study aimed to investigate the adherence to SAP national guidelines for 
orthopaedic surgery among the SVH Orthopaedic team.  
 
Furthermore, this study was designed determine the extent to which an educational 
intervention (development and distribution of local guidelines and performing face-to-face 
interactive feedback with the prescribers) would improve the appropriateness of antimicrobial 
prescribing for orthopaedic surgical prophylaxis.  
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CHAPTER 2: METHODOLOGY 
 
This research design chosen was non-randomised pre-post intervention design, with 
the pre-intervention group as the control. The study design has received both Human 
Research Ethics Committee, and Site Specific Assessment approval at St. Vincent’s Public 
Hospital Sydney (LNR/15/SVH/92; 7 April 2015.) The study was supported by the St. 
Vincent’s Public Hospital Sydney Antimicrobial Stewardship (AMS) committee; and 
externally by the School of Pharmacy of the University of Queensland (SOP, UQ).  
 
This project was carried out in 3 phases: 
 Phase 1: A baseline retrospective audit of prophylactic antibiotic use in the setting of 
orthopaedic surgery 
 Phase 2: Intervention phase involving feedback to prescribers and local guideline 
dissemination 
 Phase 3: A repeat of the baseline audit to evaluate the success fo the intervention.  
 
Prior to this intervention, SVH had no hospital-composed SAP guidelines in place for 
clinicians as a reference. The AMS committee had suggested clinicians follow the 
recommendations of the TG version 14. In reality, many practitioners brought in different 
ideas31. Thus the intervention was to prepare a hospital guideline based on TG and other 
authoritative references; as well as to distribute the guideline and feedback face-to-face with 
the prescribers in order to raise adherence and improve patient outcomes. 
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Adherence to guidelines was subdivided into 5 categories (Table 1)  
Table 1. SAP Adherence to Guidelines criteria  
Categories Details 
 
Right drug Appropriate antibiotic agent chosen as per compliance criteria*  
(according to specific patient parameters such as allergy) 
Right drug + dose If the antibiotic was considered appropriate, the dose administered 
would be assessed based on patient’s weight. 
This aspect was automatically considered ‘non-adherent’ if the agent 
chosen was inappropriate. 
Right timing A SAP dose administered within the specific time frame prior to the 
first incision (recorded by comparing administration time against 
incision time in the patient’s medical notes.) 
This is independent of the appropriateness of the drug chosen; i.e. 
even if the antibiotic used was incorrect, its administration time would 
still be evaluated. 
Right duration Antibiotic ceased within acceptable duration after the completion of 
surgery, if not given as a single dose.  
This was evaluated by comparing the time of last dose administered 
against out-of-theatre time (as exact wound closure time was not 
noted on any record forms.) 
This is independent of the appropriateness of the drug chosen. 
 
Overall adherence Adherence to all four aforementioned categories. 
If any category was considered non-adherent while data for other 
categories was not assessable, administration was considered overall 
non-adherent. 
*Adherence criteria refer to the expected standard of practice at the time of investigation; details of 
criteria differed in Phase 1 & 3 due to changes in TG recommendations between 14th and 15th editions. 
Please see the following sections for details. (Table 2 & 3) 
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The four categories (apart from overall adherence) were chosen as appropriate spectrum of 
coverage, adequate dose to reach MIC, timely administration and suitable duration are the 
critical aspects that determine the success of SAP, according to consensus guidelines32.  
 
After considering similar studies worldwide28, 33 and practical limitations, the 
following inclusion and exclusion criteria were employed. 
 
Inclusion criteria: 
 Adult patients (16 years and older) presenting to St. Vincent’s Public Hospital and 
receiving orthopaedic surgery requiring SAP within the specified time-frames, whether 
emergency or elective surgery.  
 
Exclusion criteria: 
 Patients treated for other active infections, non-clean wounds where antibiotics used 
cannot be differentiated from SAP3.  
 Major breakthrough in aseptic technique during surgery; where an antibiotic is required 
post-operation and cannot be differentiated from SAP. 
 Patients receiving surgeries in multiple sites; where SAP for other sites cannot be 
differentiated from SAP due to operation of interest. 
 Revised surgeries14, i.e. patient requiring a second operation due to failure of the first 
procedure.  
 
In this study, orthopaedic surgeries requiring SAP were determined to be hip replacement, 
knee replacement and open reduction with internal fixation (ORIF). Spinal surgeries were not 
included since they were performed by the neurosurgery team not involved in this project. 
Arthroscopies for immunocompromised patients were not included due to difficulty in 
defining ‘immunocompromised’ retrospectively.  
 
Data was partially included if certain aspects were identified as part of SAP. For 
example, if a patient was given cefazolin 500mg 30 minutes before surgery as per the 
operation schedule and continued for 3 extra days due to confirmed urinary tract infection, 
the drug option and timing would be considered ‘adherent’, dose ‘non-adherent’ and duration 
‘not assessable’. 
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2.1 Phase 1 Pre-intervention audit 
 
The Phase 1 audit was carried out retrospectively to obtain baseline data.  The project 
team chose not to ‘prospectively’ collect data from the anaesthetic record while the patient 
was in theatre to avoid any bias caused by the physical presence of a project team member 
during SAP prescribing. 
 
Clinical data of patients who underwent orthopaedic surgeries that met the inclusion 
criteria between the periods August to October 2014 were collected between May and July 
2015, using a drug use evaluation (DUE) instrument (Appendix 1.) The instrument was 
developed by the project team based on SAP guideline requirements and was approved by the 
SVH AMS committee prior to study commencement.  
 
The patient list was first obtained from the Coding unit of Medical Records 
Department using the terms and procedure codes listed in Appendix 2. Relevant procedure 
names and codes were extracted from the coding reference ‘Procedures on musculoskeletal 
system’ supplied by the Coding unit. A list of patient names and their unique unit record 
(MRN) was generated according to the codes. The list was then submitted for patient files to 
be extracted for data collection. 
 
All data were retrieved from paper-based anaesthetic records obtained from the SVH 
Medical Records Department. Missing information (e.g. patient weight, relevant 
microbiology lab results and post-surgical antibiotic administrations in wards) was 
supplemented by using WebdeLacy© and Medchart© – electronic medication management 
systems used in SVH. (For details of sources of data, please see Appendix 3). To ensure the 
confidentiality of included participants, all patients were given a unique participant code 
comprised of their initial and the last 2 digits of their MRN. The data collected and the 
participant code-MRN correspondence page were saved into 2 separate Excel files.  
 
In order to measure the appropriateness of SAP prescribing and provide an adherence 
rate to guidelines, the collected data were compared against the ‘appropriateness of SAP’ 
criteria listed in Table 2. These criteria were based on TG version 14 (which prescribers were 
advised to follow by the SVH AMS team during the time frame of the baseline audit, ASHP 
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guidelines and other relevant studies. These criteria were also reviewed by the AMS 
committee before being employed in this study. 
 
Table 2: Appropriateness of SAP criteria 
Parameter SAP criteria34 
 
Drug & Dose# Cefazolin 1g (2g if patient no less than 80kg) or  
Flucloxacillin 2g or  
Vancomycin* 25mg/kg (max 1g) 
Timing Cefazolin within 60minutes before incision  
Flucloxacillin within 60minutes before incision  
Vancomycin infusion to be ended just before procedure 
Duration Single dose accepted; 
Repeat dose during operation accepted if surgery is longer than 4 hours; 
If continued after surgery, last dose to be given within 24 hours of 
operation completion 
Overall Adherence to all of the above parameters 
#Doses are for adult use as SVH has no paediatric orthopaedic ward. 
* Selection of vancomycin considered appropriate if any of the following met: (i) infected/colonised 
with MRSA currently or in the past; (ii) high risk of MRSA colonisation (e.g. inpatient ≥ 5 days before 
surgery; (iii) immediate-hypersensitivity to penicillins and/or any hypersensitivity to a cefalosporin 
 
Each SAP administration was assessed separately. For example, if one patient was 
given both cefazolin and gentamicin, the two administrations would be documented 
separately.  
 
2.2 Phase 2 Intervention - Feedback 
 
International studies have suggested the importance of having SAP guidelines in 
place33; however the effective implementation of guidelines is of equal importance23, 35  when 
aiming at quality improvement. Furthermore, feedback on prescription behaviour was also 
shown to improve prescribing appropriateness 36 . In order to optimise outcomes, the 
intervention phase of this study was designed to involve the reflection of Phase 1 results to 
the prescribers, as well as the dissemination of in-hospital guidelines developed by the AMS 
committee (Appendix 4) 
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The project team had initially planned to reflect the findings to the orthopaedic 
surgeons by e-mail or other paper-based methods. However, after considering the importance 
of inter-professional interaction during the feedback process4, a direct means of 
communication was sought. The intervention was performed in March 2016 as a single face-
to-face, 30-minute group feedback session with Questions and Answers to all Orthopedic 
surgeons, conducted by the primary investigator on behalf of the project team. This session 
was carried out during the Orthopaedic team’s quarterly departmental meeting after obtaining 
their consent to participate.  
 
2.3 Phase 3 Post-intervention audit 
 
Phase 3, the post-intervention audit, was conducted between June to September 2016. 
It was conducted in an identical manner to the Phase 1 study, with medical records of patients 
who met the inclusion criteria being audited against the DUE instrument during the period 
May to July 2016. Results of the Phase 1 and Phase 3 audits were compared against each 
other and with the in-hospital guidelines (Appendix 4).  
 
During the study period, the Australian TG published an updated Antibiotic guideline 
(version 15) which included some changed recommendations on surgical prophylaxis. The 
main adjustments included a change in dosing of cefazolin and allowance of the combination 
of cefazolin and a glycopeptide9. Although surgeons were encouraged to adhere to the in-
hospital guidelines developed and distributed in Phase 2, all SAP administrations according 
to TG version 15 were also considered appropriate for study purposes. One example of 
potential conflict was where the in-hospital guidelines adopted the use of teicoplanin based 
on feasibility issues and evidence-based studies; however prescribers using the TG version 15 
recommendation of vancomycin would also be considered adherent (Table 3). Due to these 
criterion changes, prescribers were considered adherent if they met the criteria of either of 
these guideline versions.  
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Table 3.  Comparison of SAP criteria in Phase 1 and Phase 3 
Parameter Phase 1 SAP criteria  
 (TG Antibiotic version 14)34 
Phase 3 SAP  criteria  
(TG Antibiotic version 15)9 
Drug + 
Dose 
Cefazolin 1g  
(2g if patient no less than 80kg) 
or  
Flucloxacillin 2g  
or  
Vancomycin* 25mg/kg (max 1g) 
Cefazolin 2g  
(optional 3g if patient >120kg)   
 
If MRSA coverage needed and no 
immediate penicillin/ cefalosporin 
allergy:  
add Vancomycin 15mg/kg (max 1g) or 
Teicoplanin 800mg 
 
If patient has immediate penicillin / 
cefalosporin allergy: use only 
Vancomycin or Teicoplanin 
Timing Cefazolin within 60minutes 
before incision  
Flucloxacillin within 60minutes 
before incision  
Vancomycin infusion to be 
ended just before procedure 
Cefazolin within 60 minutes  
before incision  
Vancomycin infusion to be started  
30-120 minutes before incision 
Teicoplanin 30 minutes prior to incision 
Duration Single dose accepted; 
Repeat dose during operation 
accepted if surgery is > 4 hours; 
If continued after surgery,  
last dose to be given within 24 
hours of operation completion 
Cefazolin & Vancomycin to be ceased 
within 24 hours of operation completion. 
Teicoplanin not to be re-dosed.  
Overall Adherence to all of the above parameters 
 
Phase 3 data was again collected retrospectively, with the same project team member 
(lead investigator) collecting the data for both Phase 1 and Phase 3 of the study. Files were 
retrieved from the Medical Records Department after they had been coded, approximately 
one month after patient discharge.  
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2.4 Study timeline 
 
The timeline for the three phases of the study are outlined in Table 4.  
 
Table 4: Study timeline 
Activities Period 
Project draft with SOP, UQ 
 
Dec 2014 – Jan 2015 
Liaise with SVH (Pharmacy) 
 
Jan 2015 
 
Liaise with SVH (AMS committee, Orthopaedic team) 
 
Feb 2015 
 
Approval of project protocol and DUE instrument by AMS 
 
Feb 2015 
 
Human Research Ethics Committee application submitted 
 
Feb-Apr 2015 
 
Ethics, science, and Site specific assessment approval 
 
Apr 2015 
 
Liaise with SVH Medical Records Department 
 
Apr-May 2015 
Phase 1 pre-intervention data collection 
 
May-Jul 2015 
 
Phase 1 data analysis and team feedback;  
SVH guideline prepared by AMS committee 
 
Aug-Oct 2015 
 
Feedback arrangement with Orthopaedic team 
 
Oct 2015 – Feb 2016 
 
Phase 2 intervention – feedback to prescribers provided 
 
Mar 2016 
 
Washout phase 
 
Mar – Apr 2016 
 
Phase 3 post-intervention data collection & analysis 
 
Jun-Sep 2016 
 
Thesis completion 
 
Sep 2016 
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CHAPTER 3: RESULTS 
 
3.1 Phase 1 Pre-intervention audit   
 
In Phase 1, data associated with 93 SAP administrations were collected; from a total 
of 77 patients. Of these 93 administrations, there were 32 assessable administrations from hip 
replacement surgeries (24 patients), 21 from knee replacement surgeries (15 patients) and the 
remaining 37 were from ORIF cases (which formed the greatest group). ORIF cases had 38 
patients and 40 administrations to begin with; however, three of them could not be assessed 
due to poor recording (e.g. dose not documented on Anaesthetic & Recovery record) or 
meeting exclusion criteria (i.e. patient received active treatment for infection and the 
antibiotic cannot be differentiated from SAP). A detailed comparison of the pre- and post-
audit results is provided in section 3.4.  
 
3.2  Phase 2 Intervention - Feedback 
 
During the 30-minute face-to-face, group feedback session attended by the 
Orthopaedic and the project team, the lead investigator provided feedback to the participants 
on their division’s performance on the baseline SAP audit; and provided an opportunity for 
these prescribers to reflect on their practice. The session was also used to introduce and 
disseminate the local SAP guideline developed by the AMS committee. Care was taken by 
the project team to convey respect and an encouraging attitude towards the orthopaedic 
surgeons when comparing actual local performance against best practice.  Table 5 briefly 
describes the structure and content of feedback provided and sought at the intervention 
session.   
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Table 5: Content of the intervention session 
Explained the aim of the study 
 Quoted results from NAPS – which suggested local poor adherence to guidelines across 
all types of surgery.  The AMS committee wanted to identify the adherence rates of the 
Orthopaedic team independently. 
 Mentioned changes in the recommendations of TG ver. 15. Briefly explained the clinical 
implications of the new recommendations. 
 Clarified that the study is to assist in the prescribers’ decision-making in the future, 
instead of ‘judging’ their critical thinking.  
 
Explained the study design 
 Expounded the 3 phases of this pre-post interventions project. 
 Stated inclusion and exclusion criteria; as well as the compliance criteria. 
 Mentioned the number of cases collected. 
 
Elaborated on major findings from the Phase 1 study 
 Diagrams, tables and figures presented  with  antibiotics prescribed, drug + dose, timing, 
duration and overall adherence  rates. 
 Overall results and results for each type of orthopaedic surgery were presented. 
 
Positive reflection 
 Positively reflected on the aspects performed in accordance to adherence criteria.  
 Commended surgeons in reaching satisfactory adherence in terms of drug choice and 
duration of SAP. 
 
Indicated areas for improvement 
 Listed the use of inappropriate antibiotics such as gentamicin and ciprofloxacin. 
 Reported on the under-dosing of SAP. Reminded prescribers to observe the weight-
based dosing threshold. 
 Reflected that most cases non-adherence to timing was when given antibiotic was 
administered too late (after incision). 
 All cases of non-adherence to duration received antibiotic for a prolonged period (> 24 
hours) after wound closure. 
 In order to show the teams’ respect to the surgeons’ effort, a positive attitude was 
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maintained when pointing out their mistakes. Convinced the prescribers that if they have 
treated the operation as ‘polishing an artwork’, they would not want a tiny negligence to 
the SAP (e.g. injection inappropriately delayed for 15 minutes) to ruin their 
‘masterpiece’. 
 
Explained the importance of concordance 
Failure to comply with SAP guidelines may lead to: 
 Higher risk of SSIs. 
 Higher risk of bacterial resistances development. 
 Higher risk of adverse drug reactions including superinfections. 
 
Mentioned comparisons  
 Compared SVH findings with similar studies identified in literature review. 
 Highlighted that the Orthopaedic team had performed satisfactorily in general; however, 
the team should always aim at improving their results. 
 
Invited the surgeons to voice  their concerns 
 Asked for their interpretation of the reasons for non-adherence by using open-ended 
questions.  
 Actively listened to their perceived differences between the team’s usual practices against 
what was suggested by the evidence. 
 Encouraged them to ‘challenge’ our study in terms of design and results; as by 
constructive peer discussion, both the project team and the surgeons would more likely 
identify practice gaps. 
 Encouraged reflection on their understandings of the SAP guidelines. 
 
Introduced  the in-hospital guidelines 
Introduced the newly released SVH in-hospital SAP guidelines, with salient details 
highlighted by the Infectious Diseases physician in the project team. By increasing prescriber 
understanding of the guidelines, the team hoped to promote adherence. 
 
Post-intervention phase (Phase 3) 
Provided overview of the post-intervention audit to be carried out in two months’ time. 
 
Time for Questions & Answers 
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A summary of the feedback session was also filed into the Orthopaedic team meeting 
minutes for surgeons’ review in the future. 
 
3.3 Phase 3 Post-intervention audit  
 
In Phase 3, data associated with 89 SAP administrations were collected from a total of 
80 patients. Of these, 20 assessable administrations were from hip replacement surgeries (17 
patients), 16 from knee replacement surgeries (13 patients) and 53 administrations (50 
patients, with one patient having two separate surgeries during the study period) from ORIF, 
which once again contributed to the greatest cohort. Unlike Phase 1, no administrations were 
completely non-assessable; however, multiple cases could only be assessed partially due to 
poor recording (1 administration) or only partially meeting the inclusion criteria in a certain 
aspect (6 administrations.) Unfortunately two patients (apart from the 80 included) who met 
the inclusion criteria could not be fully assessed because their medical record files were 
transferred to a rehabilitation hospital during the study time frame.  
 
3.4 Comparison of pre- and post- intervention audits (Phases 1 and 3) 
 
3.4.1 Distribution of surgery types 
 
Figure 1A & 1B below illustrated the proportion of different orthopaedic surgeries in 
Phases 1 and 3 of this study respectively.  
 
Figure 1A: 
Distribution of surgery types
(based on phase 1 assessable administrations)
N=90
36%
23%
41%
Hip replacement
Knee replacement
Open reduction with
internal fixation
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Figure 1B: 
Distribution of surgery types
(based on phase 3 assessable administrations)
N=89
22%
18%60%
Hip replacement
Knee replacement
Open reduction with
internal fixation
 
 
With approximately the same number of administrations, there were a larger 
proportion of ORIF cases in Phase 3. This can possibly be explained by the difference in 
study period. Phase 1 included data from August to October 2014, when many elective cases 
of hip and knee replacement surgeries were rushed to finish before Christmas. In comparison, 
Phase 3 comprised operations conducted in May to July 2016, when there was less pressure 
to complete the joint replacement operations.  
 
3.4.2 Comparisons of patient gender and age 
 
Figures 2A & 2B compare the gender distribution of the three surgeries in both phases. 
Overall, there were more female than male patients in both phases: 33 males vs 44 females in 
Phase 1, compared with 30 male vs 50 female in Phase 3. With the exception of knee 
replacement surgeries in Phase 1, female patients had a higher likelihood of undergoing 
orthopaedic surgery than their male counterparts.   
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Figure 2A: 
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Figure 2B: 
 
Gender distribution (Phase 3)
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In Phase 1, the median age of patients receiving a hip replacement was 77.5 years; 
while patients having ORIF surgeries had a considerably younger median age of 51.5 years 
(Figure 3A). In Phase 3, hip replacement patients still had the highest median age of 73 years; 
however the median age of ORIF patients rose to 62.5 years (Figure 3B). Nevertheless, given 
that age and renal function are not factors impacting on SAP options9, 16, this would not 
significantly affect the study results.  
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Figure 3A: 
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Figure 3B: 
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3.4.3 Comparison of adherence rates 
 
Table 6 summaries the adherence rates across specified orthopaedic surgeries and 
SAP criteria.  
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Table 6 - Adherence rates by type of orthopaedic surgery and SAP criteria  
Surgery type + 
Parameter 
Adherence rates (Phase 1) Adherence rates (Phase 3) p-value 
All surgeries Overall 32.2% N=90 56.1% N=82 0.002 
All surgeries 
Drug option 
72.2% N=90 88.4% N=86 0.007 
All surgeries 
Drug + Dose 
41.1% N=90 77.9% N=86 <0.001 
All surgeries 
Timing 
72.2% N=90 88.4% N=86 0.007 
All surgeries 
Duration 
80.4% N=92 72.5% N=80 0.219 
Hip replacement 
Overall 
37.5% N=32 47.4% N=19 0.489 
Hip replacement 
Drug option 
65.6% N=32 80% N=20 0.352 ($) 
Hip replacement 
Drug + Dose 
46.9% N=32 70% N=20 0.102 
Hip replacement 
Timing 
65.6% N=32 94.4% N=18 0.036 ($) 
Hip replacement 
Duration 
68.8% N=32 52.9% N=17 0.275 
Knee replacement 
Overall 
28.6% N=21 43.8% N=16 0.338 
Knee replacement 
Drug option 
52.4% N=21 68.8% N=16 0.315 
Knee replacement 
Drug + Dose 
33.3% N=21 68.6% N=16 0.033 
Knee replacement 
Timing 
66.7% N=21 75% N=16 0.723 ($) 
Knee replacement 
Duration 
85.7% N=21 50% N=16 0.03 ($) 
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ORIF 
Overall 
29.7% N=37 63.8% N=47 0.002 
ORIF 
Drug option 
89.2% N=37 98% N=50 0.159 ($) 
ORIF 
Drug + Dose 
40.5% N=37 84% N=50 <0.001 
ORIF 
Timing 
81.1% N=37 90.4% N=52 0.205 
ORIF 
Duration 
87.2% N=39 87.2% N=47 0.994 
Sample size N is based on number of administrations.  
P-values are derived from Pearson Uncorrected Chi-Square tests37; except those marked with ($), 
which are based on results of two-tailed Fisher Exact test due to at least 1 cell with sample size38 less 
than 5 (I.e. N<5.) 
P-values are calculated using online calculator39. 
Significant values (p<0.05) have been highlighted in red. 
 
Before the interventions in Phase 2, the overall adherence rate, taking into account all 
three types of orthopaedic surgeries, was 32.2%. This implied that 2 out of 3 SAP 
administrations were inappropriate in one or more parameters. This adherence rate increased 
to 56.1% after the face-to-face feedback session with the prescribers and distribution of in-
hospital guidelines; meaning that less than half of the administrations was non-adherent, a 
statistically significant change (p=0.002.) 
 
When considering the results of all three surgeries together, adherence rates in terms 
of drug choice, drug + dose and timing all increased significantly. However, the adherence 
rate to SAP duration decreased in Phase 3, although the difference was not statistically 
significant. 
 
The overall adherence rate for all three types of surgeries showed an increase; 
however only the difference in ORIF cases was statistically significant. This could be due to 
the limited sample sizes in hip and knee replacement operations. Hip replacement surgeries 
had the highest overall adherence rate in Phase 1, while ORIF topped the list of all three 
surgeries in Phase 3. This dramatic trend should be interpreted together with the adherence 
rate changes of each individual doctor, which is presented in Figure 8.  
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Improvement in adherence to SAP dosing was the most apparent out of all parameters, 
in terms of both overall and each individual type of surgery. There was a significant rise of 
more than 100% (relative increase) in both knee replacement and ORIF cases. Conversely, 
the adherence rates to SAP duration worsened for all surgeries; with the knee replacement 
operations most obvious.  
 
3.4.4 Trends of non-adherence 
 
3.4.4.1 Drug choice 
 The patient number has increased slightly from 77 to 80 when comparing the two 
phases, however, the total number of administrations dropped from 90 to 89. The implication 
is that fewer patients had received dual agents of SAP. 
 
Figure 4 
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Figure 4 above illustrated the percentages of patients who have received more than 
one SAP agent, where at least one agent was inappropriate. These included patients who were 
given unnecessary vancomycin on top of cefazolin, as well as those whom received the 
combination of vancomycin and ciprofloxacin/gentamicin. The 58.8% relative reduction in 
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this figure reflected that, after the interventions, fewer prescribers tended to add an 
unnecessary antibiotic to cefazolin. 
  
3.4.4.2 Dose 
In Phase 1, 28 administrations across all 3 types of orthopaedic surgeries consisted of 
a wrong dose despite the right antibiotic being chosen. Three quarters of these were under-
doses as shown in Figure 5. Many patients were given an insufficient dose of cefazolin 1g 
when they weighed above 80kg. This was especially common in emergency cases (e.g. an 
accidental bone fracture instead of a scheduled joint replacement surgery). One likely 
explanation is that in an emergency, the surgeons/nurses were less likely to spend time 
actually weighing the patient before an operation and instead relied on visual judgment.  
 
Figure 5 – Dosing errors 
Dosing error (Phase 1)
n=28
25%
75%
Dose too high Dose too low
 
 
In Phase 3, only 9 SAP administrations were classified as a dosing error. These 
patients were given the right drug but the wrong dose while all other non-adherence cases 
were due to inappropriate drug chosen thus dose evaluation was omitted. Out of the 9 
administrations, one involved vancomycin and the remainder involved cefazolin. Since 
cefazolin dosing has been standardised in TG version 15 as 2g for all patients9 (optional 3g 
for patients above 120kg), rarely would a prescriber ‘overdose’ this antibiotic. Therefore, it 
was not surprising that all 9 cases of dosing error resulted from under-dosing.  
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3.4.4.3 Timing 
Of the 25 cases with inappropriate timing in Phase 1, 92% of the administrations were 
given too late (i.e. the administration time was after the incision time as per anaesthetic 
record), as noted in Figure 6: 
 
Figure 6 – Timing errors 
Timing error (Phase 1)
n=25
8%
92%
Given too early Given too late
 
 
Of the 10 SAP administrations that were non-adherent to timing in Phase 3, all were 
given too late.  
 
3.4.4.4 Duration 
All 18 cases non-adherent to SAP duration in Phase 1 had prolonged administration 
beyond 24 hours for no obvious reasons (Figure 7.) When surgery was continued beyond 4 
hours on 5 occasions, all surgeons in this cohort appropriately injected a second dose of 
cefazolin. 
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Figure 7 – Duration errors 
Duration error (Phase 1)
n=18
0%
100%
Given for too short Given for too long
 
 
In Phase 3, 22 administrations out of 80 had an inappropriately prolonged duration 
beyond 24 hours post-operation. Again all of these were given for too long. As mentioned in 
Table 6, this has resulted in a worsening of the total adherence to the duration parameter as 
compared to the 80.4% adherence rate in Phase 1.  
 
Nonetheless, it was noted that more prescribers were willing to specify their intended 
post-operative SAP duration in the ‘post-op plan’. Common instructions were ‘24/24’ (24 
hours), ‘o/n’ (overnight), ‘total 3 doses’ as compared to simple directions ‘ivabx’, ‘cont. abx’ 
in Phase 1. Out of the 22 non-adherent administrations, 11 actually had an adherent direction 
on the post-op plan. They were, however, administered inappropriately after handing over to 
the physicians on ward level. Assuming the 11 administrations were given to the patients 
correctly as per the Orthopaedic team’s intention, the adherence rate to duration taking into 
account all surgeries would increase from the present 72.5% to 86.3% (58/80  69/80.) 
Though this was unlikely to be statistical significant.  
 
3.4.5 Adherence rates for individual prescribers 
 
There were 6 major surgeons in the SVH orthopaedic team; together with their 
assistant surgeons (which may occasionally change). These surgeons have performed no less 
than five surgeries (all three types of operations together) in either phases of the study. They 
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are named Teams A-F in Figure 8 below. Another four relatively new surgeons who 
performed less than 5 operations in both or either phase are grouped under Team G. 
 
Figure 8 – Adherence rates based on doctors 
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Each coloured line represents one surgeon team. The left side of the lines represents 
each team’s overall adherence to SAP in Phase 1, while the right side of the line, Phase 3. 
The rates were calculated by dividing each team’s number of adherent SAP administrations 
(overall) by total number of administrations performed by them. For example, team A (dark 
blue line) was responsible for 8 administrations in Phase 1 across all three surgeries; 5 of 
these were overall adherent to SAP guidelines (i.e. correct in all parameters), thus yielding a 
62.5% adherence rate. In phase 3, they performed 11 administrations, of which 7 were overall 
adherent; thus the adherence rate slightly increased to 63.6%. Team B, who performed 12 
administrations in Phase 1 and 10 administrations in Phase 3, yielded complete non-
adherence in both phases and became the worst performing team. Team B mainly 
participated in hip & knee replacement cases; this may be a major reason for the minimal 
improvement in SAP adherence post-intervention in these two surgery types. All other teams 
   
 Page 34  
had an elevation in adherence rates to different extent; teams D, E & G have demonstrated 
amazing improvement after the intervention. 
 
3.4.6 Other non-statistical findings from patient files review in Phase 1 and during 
the feedback session 
 
Gram negative coverage Some surgeons have raised the concerns of lack of Gram 
negative coverage for urinary-catheterised patients. Some have 
added the administration of gentamicin for this reason. 
 
Extended duration for 
urinary-catheterised patients 
Some surgeons were concerned with the lack of antibiotic 
coverage for catheterised patients post-operatively, thus 
continued the SAP beyond the recommended 24 hours until all 
drains and catheters were removed.  
 
Communication problems The post-operation plan was a major route of communications 
between Orthopaedic surgeons and ward doctors; thus any 
unclear instructions should be avoided. 
 
One example was a surgeon writing ‘post-op antibiotics X3’ 
on the plan, which he/she meant 3 doses (to be completed 
within 24 hours); and was interpreted as ‘3 days’ by ward 
doctors. The patient was given 2 extra days of unnecessary 
SAP. 
 
Poor recording In two cases, SAP was ticked on the surgical safety checklist 
‘team time out before skin incision form’, but the agent(s) 
used, the dose and timing were not recorded on the anaesthetic 
record.  
 
This reminded surgeons that the anaesthetic record is the only 
evidence of SAP administration, thus should always be 
documented for both good practice and legal reasons.  
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CHAPTER 4: DISCUSSION 
 
SVH, as a tertiary hospital in Sydney, Australia, had a relatively high adherence rate 
to national guidelines even before the intervention. Although NAPS results suggested room 
for improvement, the Orthopedic team’s adherence rates to guidelines was satisfactory as 
compared to studies carried out overseas13, 14, 20, 21, 22, 23.Given the relatively higher baseline 
adherence level to SAP pre-intervention, one would have expected the improvement to be 
minimal26. Nevertheless, our project successfully improved the overall adherence rates to 
SAP by 23.9% absolute difference. 
 
Studies worldwide have investigated the reasons of non-adherence to SAP guidelines 
among prescribers17, 23, 33. Although many suggestions have been made, the lack of on-site 
guidelines33 and failure to disseminate on-site guidelines to clinicians17, 23 were two of the 
most commonly attributed causes. Our study aimed to bridge this gap by developing an in-
hospital guideline based on the TG and distributing it together with feedback on the 
prescribers’ performances. The results have been positive. The overall adherence rate in our 
study, taking into account all three types of orthopedic surgeries, has increased significantly 
from 32.2% pre-intervention to 56.1% post-intervention (p=0.002). This reflected that the 
interventions had successfully increased the prescribers’ awareness to appropriate SAP 
administration. It also implied an increased knowledge and acceptance of guidelines.  
 
When faced with the lack of awareness of recommendations from national guidelines, 
prescribers tend to rely on memory of initial training13 (which may be incorrect or obsolete), 
discussion with peers17 and even internet resources13 to make decisions regarding SAP. Our 
intervention of preparing a readily available in-hospital guideline has clarified the current 
evidence-based recommendations to assist the prescribers in removing the obstacle related to 
inadequate information when making judgments. With the SAP guidelines clearly presented 
and explained, our adherence rates substantively improved. This concurs with literature 
findings in other settings27.  
 
The development of on-site guidelines alone is unlikely to be successful unless there 
is an opportunity for the message to not only to be effectively passed on to the prescribers, 
but also for them to reflect on their performances4, i.e. what behavious were non-adherent 
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and strategies for improvement. The face-to-face feedback session held by the project team 
has served this purpose. Rather than delivering our results from Phase 1 via e-mail or mail, 
we chose an interactive education session to involve the prescribers in decision making, with 
promising results, as reflected in the increased adherence rates. Other investigators believed 
that this is partly due to an increase in sense of ownership to the developed guidelines10 and 
triggered recognition among individual surgeons that their usual practices do not comply with 
peer standards4. We agree with this explanation; as prescribers were seen to be actively 
asking questions and trying to digest the recommendations during the feedback session. ‘Can 
you elaborate a bit more about the drug resistance part?’ ‘So how bad is it if I, say, gave the 
antibiotic right after cutting open the wound?’ ‘What do you mean by the ward doctors 
misunderstanding our post-op plan?’ These were three of the questions raised by the 
attending surgeons.  
 
The key to a successful interaction that leads to positive behavioural changes is a 
respectful and professional attitude being maintained when providing feedback to a group of 
peers40, 41.  In our feedback session, the surgeons’ dedication to patient-care was 
acknowledged during the reflection. The motivation of the project team to highlight areas 
with room of improvement was in hope of enhancing quality use of medicines, rather than 
judging the mistakes of the prescribers. All questions raised by surgeons were answered in a 
professional manner and supported by adequate evidence from literature. One example was 
the reason to not include gentamicin in SAP for orthopaedic surgeries – because Gram 
negative coverage was not shown necessary for urinary catheters; and that cefazolin has 
provided sufficient protection42.  
 
Some investigators have also proposed that low adherence rates imply underlying 
conflicts, in the prescribers’ minds, between perceived clinical benefit to an individual patient 
and a theoretical risk to the entire community caused by lowered antibiotic sensitivity43. The 
increase in adherence rates post-intervention in our study may suggest that the feedback 
session has, to certain extent, resolved this conflict. During the interactive discussion, 
prescribers were encouraged to raise their concerns about the recommendations in the 
guidelines. This question & answer process triggered prescribers to recognise that their usual 
practice may be in conflict with the quality use of medicines.  
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The adherence rates of SAP administration and its changes following the 
interventions can be elaborated in regard to drug choice, dosing, timing and duration: 
 
4.1 Interpretation of results for individual SAP criteria 
 
4.1.1 Antibiotic option 
 
Studies performed in other countries have noted an adherence rate to the SAP 
antibiotic option of less than 70%17, 44.  This rate was similar to the results in our pre-
intervention audit. In the Phase 3 post-intervention evaluation of our study, the appropriate 
choice of antibiotic agents among all surgeries had significantly increased from 72.2% to 
88.4% (p=0.007). This reflected the surgeons’ increased willingness to choose the antibiotic 
suggested by the in-hospital guidelines. It was also pleasing to see that after having an 
opportunity to explain to prescribers the rationale for using cefazolin in orthopaedic SAP, its 
rate of usage increased dramatically.  
 
Cefazolin has long been the drug of choice for orthopaedic SAP9, 16, 19 and most 
surgeons were aware of this recommendation. However, some prescribers in our study had 
chosen cefalosporins with broader coverage (e.g. second or third generation agents) for 
various reasons. This reflected the necessity of interpreting the guidelines for prescribers to 
raise their understanding of antimicrobial spectrum and its implications for SSI and the 
development of resistance. 
 
The feedback session provided the project team with an opportunity to explain why 
cefazolin was recommended. It was reinforced that antibiotics with more advanced coverage 
do not provide better outcomes in terms of SSI rates12. This is because cefazolin has the 
ability to cover the most common pathogens9, 45. Having the black-and-white guidelines 
interpreted orally reassured the prescribers that their decision to not use ‘big-guns’ would not 
pose a greater threat to their patients. The project team also used the opportunity to remind 
prescribers that over-consumption of broad-spectrum antibiotics unnecessarily may lead to 
emergence of bacterial resistance and superinfections including MRSA, extended-spectrum 
beta-lactamase (ESBL) producing organisms, vancomycin-resistant enterococcus (VRE) and 
Clostridium difficile (C difficile)46,47. This is a basic concept that all prescribers have in mind, 
but may have overlooked in practice. By reporting the studies of Fukatsu et al48 which 
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concluded that overuse of third generation cefalosporins led to MRSA outbreaks, prescribers 
were more easily convinced that broader spectrum antibiotics may actually cause harm to 
patients rather than increasing protection in orthopaedic SAP. This concordance was reflected 
in the increased adherence to the in-hospital guideline seen in Phase 3.  
 
Importantly, in our study, fewer patients received an unnecessary antibiotic for SAP 
in Phase 3. This improvement was largely due to the reduced consumption of vancomycin 
and gentamicin when they were not indicated. Many prescribers have misconceptions as in 
when to employ vancomycin in orthopaedic SAP. As the change in TG recommendations 
further complicated this issue, the project team made use of the feedback session to clarify 
the matter.  
 
It is clearly stated in the TG that the routine use of vancomycin is not supported9; 
however its combination with cefazolin is justified if the MRSA SSI rate is no less than 
0.25% and other infection rates are no less than 0.2%49. Archer50 reported that cefazolin and 
vancomycin had demonstrated similar SSI rates; the former was related to MRSA SSIs and 
the latter MSSA SSIs. One possible explanation was the choice of SAP antibiotic changing 
the flora of infection but not the risk of SSI itself50. This could explain why the two agents 
were used together in certain scenarios to avoid both MRSA & MSSA SSI in high risk 
patients9. The reduced combination rate observed in Phase 3 of our study suggested this 
clarification let to prescribers being more confident in when to employ the combination.  
 
Taking into account practical issues, teicoplanin was accepted in Phase 3 of our study, 
given its equivalent SAP status as vancomycin. Meta-analysis has demonstrated no SSI risk 
difference between teicoplanin and cefazolin16. Teicoplanin had advantages over vancomycin 
due to its ease in administration45, less risk of red-man syndrome, longer half life (thus no re-
administration required), lower toxicity and good tissue penetration which allows 
achievement of therapeutic concentration in bones and surrounding tissues during 
orthopaedic surgeries51. Its acceptance in SAP use is based on scientific evidence beyond the 
recommendations from TG; and so made the in-hospital guideline more localised for use in 
SVH. This idea of tailor-made on-site guidelines may have increased the sense of ownership 
among the Orthopaedic surgeons; which in turn promoted adherence.  
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It was observed that one ORIF patient whom had stayed in hospital more than 2 
weeks within 3 months of their orthopaedic surgery (thus indicated for use of a glycopeptide 
as SAP) was appropriately prescribed teicoplanin. In contrast, one ORIF patient who should 
have received teicoplanin due to hospitalisation beyond 2 weeks in the previous 3 months 
before surgery, was not given the medication. One knee replacement patient was 
administered teicoplanin with no obvious reasons. This reflected that although the addition of 
teicoplanin to in-hospital guidelines was of benefit, the education on how to best administer 
the antibiotic (or glycopeptides in general) needs to be strengthened. 
 
There was intense discussion regarding the need for gentamicin in catheterised 
patients during the feedback session. Many doctors had the misconception that Gram 
negative coverage is essential in orthopaedic SAP to prevent urinary tract infections in 
patients with catheters in-situ. This observation echoes the findings by various other 
investigators52. The Infectious Diseases physician on the project team reinforced the 
recommendations from TG9 and ASHP16 guidelines that this practice has not been proven 
effective.  
 
This piece of interactive education was supported by two papers, published after the 
feedback session. A study conducted in Melbourne pointed out that catheter-associated 
bacteriuria has low incidence rates (1.4%) given that pre-admission urine analysis has been 
performed. Furthermore, all cultured organisms in prosthetic joint replacement cases were 
sensitive to cefazolin52. A pre-post intervention study, also published in 2016, demonstrated 
that the withdrawal of gentamicin cover for catheter insertion in joint replacement patients 
did not have a significant effect on the rate of SSIs or acute kidney injury53. This piece of 
information in support of our in-hospital guideline will be disseminated to the Orthopaedic 
surgeons after the completion of this project as a strategy of continuous quality use of 
medicines reinforcement. 
 
The appropriateness of clindamycin was also mentioned during the feedback session. 
The project team agreed that clindamycin covers the essential bacteria in orthopaedic 
surgeries and has been supported by some references42. However, the TG highlighted that 
glycopeptides remain the antibiotic of choice in patients who require MRSA coverage and/or 
have experienced an immediate sensitivity to penicillins9. It was important for the reflection 
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to address areas where prescribers disagree with the guidelines, as disagreement to guideline 
recommendations leads to non-adherence31. Prescribers were informed that clindamycin, 
unlike cefazolin and vancomycin, is a bacteriostatic agent instead of bacteriocidal54; and so 
has the possible risk of lower efficacy in immunosuppressed patients55.  
 
4.1.2 Antibiotic dose 
 
In our study the dosing component was considered non-adherent once the antibiotic 
agent chosen was inappropriate, because it would be meaningless to evaluate the dose of an 
antibiotic if it wasn’t suitable for the SAP from the beginning. Thus the adherence rate of 
drug+dose parameter in Phase 1 was low compared to studies worldwide17. After the 
interactive feedback and education session, the corresponding adherence rate surged 
significantly from 41.1% to 77.9% (p<0.001), with the adherence rate doubled in knee 
replacement and ORIF operations. This has undoubtedly reflected the prescribers’ 
improvement to administer the right drug+dose of SAP.  
 
In order to investigate the improvement of adherence to the dosing parameter itself, 
the number of SAP administrations with right agent but wrong dose was isolated. A major 
drop from 28 inappropriate dosing administrations in Phase 1 to nine administrations in Phase 
3 suggested that the clarification of cefazolin dosing was successful. In fact, the project team 
believes the education on the standardisation of cefazolin dosing in TG and our in-hospital 
guideline played a critical role.  
 
TG version 14 used in Phase 1 recommended the use of 1g cefazolin for patients 
under 80kg34. This has likely resulted in a high level of under-dosing as Australian men, on 
average, weighed 85.9kg56, with under-dosing potentially leading to insufficient protection 
and resultant SSIs19. Since many prescribers tended to underestimate the required dose of 
cefazolin in orthopaedic SAP, and given the relatively non-toxic nature of the antibiotic57, our 
in-hospital guideline has followed the recommendation of the TG9 and other international 
practices16 to standardise the dose of cefazolin to 2g without regard to a patient’s weight. 
During the intervention session, the project team also provided the prescribers with more 
solid evidence regarding the dose change. More resistant organisms including the coagulase-
negative Staphylococci have gained higher minimum inhibitory concentrations (MICs) 
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against cefalosporins51; leaving the traditional 1g dose of cefazolin possibly insufficient to 
protect the hosts58. Forse et al59 also questioned the suitability of using 1g cefazolin for SAP 
as a 2g dose was shown to significantly reduce the SSI risk from 16.5% to 5.6%. With these 
dosing recommendations clarified, prescribers were less concerned about over-dosing their 
patients with excessive antibiotics; thus the adherence rates for drug dosing increased 
dramatically. In fact, the improvement in SAP dosing superseded all other parameters under 
investigation in our project. 
 
It was mentioned that the SVH in-hospital guideline accepted the option of using 3g 
of cefazolin in patients beyond 120kg, however clinicians prescribing 2g would be 
considered compliant as well. The main reason is because the evidence available currently in 
support of 3g dosing is relatively weak. Studies to support such a high dose were performed 
on obese patients58 with BMI greater than 40 kg/m2. The additional of 3g dosing was mainly 
based on expert opinion rather than peer-reviewed trials57. No prescribers administered 3g of 
cefazolin in Phase 3. All patients under-dosed (given 1g) on cefazolin in Phase 3 weighed 
less than 80kg; implying that a few surgeons may have still adhered to the old guidelines. 
 
4.1.3 Antibiotic timing 
 
Adherence to the SAP timing component rose from 72.2% to 88.4% after the 
feedback session (p=0.007). Improvement to timing was also the only statistical significant 
improvement in hip replacement surgeries. Unlike other studies which have tried to improve 
SAP timing by adjustments in settings (such as changes in SAP injection location26), our 
study demonstrated an increase in adherence purely by education60.  
 
While systematic reviews have reported adherence rates to SAP timing ranging from 
22% to 100%17; it should be noted that some practices accepted SAP to be administered up to 
2 hours prior to skin incision12. The TG has, however narrowed the acceptable time between 
antibiotic administration and incision to within 60 minutes9. All surgeons that attended the 
feedback session had no disagreement on this time frame; however, not all were aware of the 
risks of SSIs when the antibiotic was given out of this golden period: 
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In 1961, Burke first demonstrated, using guinea pigs, that the appropriate timing of 
SAP to be one hour before potential exposure12. SAP administered 3 hours after inoculation 
resulted in inflammatory responses as if no SAP had been given61. The hallmark study in 
human participants which has guided the timing of SAP administration was published in the 
New England Journal of Medicine in 1992. This study demonstrated that SAP given earlier 
than 2 hours before incision and later than 3 hours after incision both resulted in a 
significantly higher rate of SSI, with a relative risk 6.7 and 5.8 respectively as compared to 
SAP administered at or within 2 hours before incision62. Several studies in the following 
decades have supported this observation17. SAP given earlier than 2 hours before skin 
incision noted a 3.8% risk of SSIs as compared to 0.6% when SAP was given appropriately. 
When the first dose of SAP was given after surgery, the SSIs rate was almost identical to not 
using any SAP31. A study published in 2007 which investigated the various risk factors of 
developing SSIs reported that timely administration of SAP was the most important 
parameter, with SAP given after incision having the highest Odds ratio of developing SSIs63. 
 
One surgeon raised the question of whether the ‘ideal timing’ should be 15-30 
minutes before incision, as stated in the TG. In fact, a few studies have tried to investigate the 
differences in SSI rates between SAP given within 30 minutes versus 31-60 minutes before 
incision. The results were contradictory64. Weber et al65 suggested that patients given SAP 
within 30 minutes of incision had a significantly high risk of developing SSIs when 
compared to SAP 31-60 minutes before operation. Conversely, Steinberg et al66 demonstrated 
a trend of higher SSI risk when SAP was given 31-60 minutes before versus within 30 
minutes of surgery (2.4% vs 1.6%) This should be interpreted with care as both studies 
included non-orthopaedic cases and antibiotic agents other than cefazolin. These antibiotics 
may have completely different pharmacokinetic characteristics when compared to cefazolin. 
In conclusion, the prescriber was reassured that SAP given within 60 minutes prior to 
operation would be considered appropriate, given the current evidence and taking into 
account the half-life of cefazolin.  
 
Unlike Phase 1, all cases non-adherent to SAP timing in Phase 3 were given after skin 
incision, instead of more than 60 minutes before. Although further improvement is to be 
strived for; the results have shown that surgeons were well aware that SAP given too early is 
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not acceptable because it may allow bacteria to invade the surgical site by the end of the 
operation before wound closure12.  
 
4.1.4 Antibiotic duration 
 
In a literature review of studies published between 1980 and 2011, ‘duration’ was the 
most common non-adherent parameter in SAP administration. Most studies have noted an 
adherence rate of less than 50%, where the most inappropriate cases were given antibiotic for 
unnecessarily prolonged periods17. The adherence rate to the duration parameter among the 
SVH Orthopaedic team was relatively higher in both study phases as compared to that 
reported by this literature review as well as the NAPS report 201424. The adherence rate, 
however, was the only parameter that saw a worsening trend post-intervention; although this 
was statistically non-significant. Interestingly, the duration of SAP post-operation was the 
most vigorously debated topic during the feedback session.  
 
There has been a large practice gap in terms of SAP duration worldwide. On the one 
hand, scientific trials have consistently confirmed that SAP administered beyond 24 hours 
after orthopaedic surgery completion provides no extra benefit42,67. On the other, prescribers 
in different countries and hospital settings have continued to dose SAP 24 hours after wound 
closure32. While this phenomenon was also observed in our study; no cases where patients 
were given a shorter than required SAP duration were recorded in either phases. Most 
surgeons were aware that surgeries prolonged beyond 4 hours (1-2 half-lives of cefazolin) or 
when the patient experienced substantial blood loss (defined as more than 1.5L) justified that 
administration of a second dose of SAP during the operation42.  
 
During the feedback session, the project team explored the medical evidence for 
recommended duration beyond the TG advice. A systematic review and meta-analysis 
publication in 2012 concluded that when comparing single dose to 2 post-op doses of same 
antibiotic in orthopaedic patients, the relative risk of developing SSI was 0.07-1.25, yielding 
a non-significant result68. Nelson et al69 stated that SAP given to orthopaedic patients for one 
day post-operatively produced no significant difference in SSI risk when compared to 7 days 
post-surgery. Prescribers were reminded that these two studies, frequently cited by 
international guidelines, had provided support that prolonging the SAP duration does not 
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improve patient outcome. Furthermore, a study of SAP in vascular surgeries demonstrated 
that coagulase-negative Staphylococcus (same bacteria as orthopaedic surgeries) has shown 
rapid development of resistance to SAP within 24 hours of administration. This significant 
fall in susceptibility continued throughout the 7 days of study70; which means that prolonged 
administration of SAP does more damage than good.  
 
Prescribers again raised the concern for protection of catheterised patients; they 
admitted this to be one of the reasons for them to order SAP beyond 24 hours in Phase 1. It 
has been clarified that such practices are not supported by the in-hospital guideline and the 
TG9. Most doctors appeared to have been convinced during the reflection session; as it was 
observed that none of the surgeons had explicitly requested continuation of SAP until 
catheter removal in the post-operative plans in phase 3. 
 
The surgeons were also reminded of the importance of clarifying their instructions for 
the duration of SAP in the post-operative period. The success of this strategy was reflected in 
the fact that more prescribers were willing to write instructions in a detailed manner in Phase 
3: ‘IV abx for 3 doses’, ‘ivabx 24/24’ ‘abx o/n’ instead of simply ‘ivabx’, ‘continue abx’, or 
‘abx X3’. However, to the project team’s surprise, the adherence rates to SAP duration 
worsened in all types of surgeries despite the seemingly fruitful feedback session. The drop 
was significant in knee replacement surgeries. This could have reflected failure of the 
educational interventions; or implied other objective factors as an obstacle in improving SAP 
adherence. 
 
During the data collection in Phase 3, the project team noted the exact phrasing used 
by the surgeons in the post-operative plan, which served as a handover document to the ward 
physicians. As mentioned in the results, 11 out of the 22 administrations that were non-
adherent to the duration parameter actually had an adherent post-operative instruction, such 
as 24/24 (24 hours post-op), o/n (overnight SAP), 3 doses ivabx (3 more doses only post-op.) 
If those instructions were followed, the duration parameter of these 11 cases would have been 
considered compliant; and the adherence rate of all surgeries would have increased from the 
present 72.5% to 86.3%, resulting in an increase in adherence rate over baseline. 
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This failure to pass the prescribing intention from surgeons to actual prescribers in the 
ward may be the real cause of failure to improve SAP duration adherence. Unlike SAP drug 
agent, dosing and timing, the duration of administration is not entirely controlled by the 
Orthopaedic team. Rather, the ward doctors whom take over the patients from the 
Orthopaedic team played a critical role. Unfortunately, this group of prescribers was not 
involved in the feedback session. The in-hospital guideline was also not targeted at this group.  
 
This observation provided inspiration on how to improve the study design in the 
future in order to yield more promising results. Interventions, including dissemination of 
guidelines and face-to-face reflection should involve all teams that participate in the process 
of patient care. Investigators conducting similar studies should plan in advance which 
departments are completely or partially involved and they should be invited to join the 
project. It was also observed that all the SAP administrations prescribed by the ward 
physicians that were considered non-adherent had been endorsed by the ward pharmacists 
(multiple pharmacists involved on rotation.) Disseldorp et al36 has recommended that 
pharmacists should be given a more active role in monitoring SAP administrations, our 
observation agrees with such suggestion. If the pharmacists were upskilled on the in-house 
guidelines endorsed by the AMS committee and the Orthopaedic team, they could optimise 
the prescribing of ward physicians. 
 
4.1.5 Individual prescribers 
 
When breaking down the SAP adherence rates, the role of different surgeons involved 
needs to be considered. 
 
Team A & C were the best performing teams in Phase 1, both of them had an overall 
adherence rate largely higher than the Orthopaedic team’s average 32.3%. After the 
interventions, their adherence rates improved marginally. Conversely, team B was the worst 
performing team in Phase 1, with 0% adherence rate overall. Team B had prescribed 
vancomycin, gentamicin and ciprofloxacin inappropriately in multiple cases (total 12 
administrations.) Their adherence rates also remained zero in Phase 3 (total 10 
administrations.) Since the major surgeon in each team remained the same in both phases, 
this reflected that best performing and worst performing prescribers tended not to be greatly 
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affected by our interventions. In stark contrast, teams D, E and F, whom had an average 
performance in Phase 1, have improved markedly after Phase 2. The adherence rates at least 
doubled after the intervention, which obviously suggests that the interventions were well 
received by these teams. In fact, it is the performance of the averagely-performing teams 
(which usually form the majority of participants) that appears to determine the overall rates 
of the entire cohort.  
 
Also worth noting is the improvement in SAP adherence among team G. Team G, 
unlike other teams, comprised of multiple surgeons that were less senior; each surgeon in the 
team has performed no more than 5 operations in either phase independently. The 
improvement in their adherence rates reflected that the message delivered by the project team 
in Phase 2 has been well received by the newer prescribers. This trend is extremely important 
because previous studies have concluded that poor initial training given to prescribers is a 
major reason for future non-adherence to SAP guidelines71. Interventions by the AMS at an 
early stage of their practice may increase their awareness and adherence to guidelines in the 
future. While interventions should ideally be aimed at all involved prescribers to yield best 
results; if limited by time, resources or other practical barriers, average-performing 
prescribers and relatively novice prescribers should be the most important cohort to target. 
 
4.2 Limitations of this project and implications for future studies 
 
4.2.1 Lack of outcome indicators as endpoints 
 
One of the major limitations of this study was the use of surrogate measurements 
instead of outcome indicators such as SSIs rates or mortality rates. As the ultimate purpose of 
carrying out this project was to improve patient outcomes, it would be reasonable for one to 
expect use of such primary endpoints. However, surrogate endpoints were justified on the 
basis that the causal relationship between SAP guideline adherence and improved healthcare 
outcomes has already been well supported by high quality studies72. 
 
The Surgical Care Improvement project developed by CDC and numerous 
authoritative organisations in 2003 has demonstrated the reduction of SSIs rates after 
following appropriate SAP measures73. An observational study published in 2006 also 
confirmed a 300% relative risk of SSIs when SAP was given inappropriately36. When 
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focusing on hip and knee replacement surgeries, appropriate SAP reduced the risk of SSIs by 
a significant 1-3%74. A study published in Taiwan in 2009 also including hip and knee 
replacement patients also confirmed that adherence to SAP guidelines reduced length of 
hospital stay, readmission risk and healthcare expenses35.  
 
In order to investigate SSI and mortality rates, the follow-up period would be up to 12 
months post operation. This was not feasible in our setting due to restrictions on time and 
resources. The small sample size available for evaluation would also affect the interpretation 
of the mortality rate. A similar study published in 2008 included more than one hundred 
patients in both the pre and post intervention period, yet they could only show a trend of 
reducing SSI after an increase in SAP adherence27. Their results were considered statistically 
non-significant; and the study itself insufficiently powered. With only approximately 70% of 
their sample size, it would have been inappropriate for our study to employ these outcome 
measures.  
 
If this study is to be performed again in the future, a larger sample size and longer 
follow-up period is recommended. As patients in Sydney may visit different hospitals in their 
lifetime, a better tracing system is also required to collect data for SSI rates and mortality 
rates interpretations.  
 
4.2.2 Hawthorne effect 
 
Hawthorne effect describes the tendency of participants of a study (the orthopaedic 
surgeons in this project) to adjust their behavior simply because they know they are being 
studied or observed75. By providing an opportunity for surgeons to reflect on their SAP 
practices and areas of non-adherence during the educational intervention, Hawthorne effect 
has been inevitably introduced to this study, leading to a confounding factor. By stating that 
the third phase, another round of SAP practice evaluation, was to be conducted in 2 months 
after the feedback session, would further alert the participants to observe the agreed in-
hospital guidelines. 
 
Changes in results simply due to attention alone is still meaningful from a practical 
point of view; as the aim of increasing adherence rates to SAP has still been attained. 
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However, the significance of the interventions was more difficult to determine. Also, the 
sustainability of the increased adherence rates remains unclear.  
 
The simplest way to evaluate the real effect of the interventions would be to set up a 
concurrent control group76. Both groups should receive pre- and post-test data analysis. The 
study group would receive the interventions, performance feedbacks and be informed of the 
in-hospital guidelines; while the control group would only be told that their performance 
would be monitored. The difference in adherence rates between the two groups would then 
take into account the Hawthorne effect. Also, a much larger sample size would be necessary 
to conduct such a study design. 
 
4.2.3 Bias due to study design 
 
This pretest-posttest study has, by definition, a quasi-experimental design77, with the 
entire group of surgeons being provided with the interventions. Without the use of a control 
group and random group assignment, the study design itself is prone to bias. While 
randomised-controlled trials are mostly impractical with quality improvement service 
research78 due to limited sample size and subject contaminations, our project team has made 
every endeavor to minimise bias within the limited available time frame to complete the 
study. 
 
We used a two-month transition/washout period between Phases 2 and 3 (March and 
April 2016) in the hope of minimising the recency effects of the interventions. Prescribers 
may be more alert about the correct SAP methods immediately after the face-to-face 
feedback; thus data collected after the 2-month washout period may be more reliable in 
reflecting long-term practices brought about by the actual influence of the strategies 
employed. We have used a single team member for data collection in both Phases 1 and 3, so 
as to minimise the variability caused by individual investigator’s interpretations of the DUE 
instrument.  
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4.2.4 Certain SAP-related antibiotic parameters not taken into evaluation 
 
Our study focused only on parameters that have been directly correlated to the 
efficacy of SAP in the literature, some other details of antibiotic administration have been 
omitted in the evaluation.  
 
Prolonged pre-op SAP has been a phenomenon described by some studies79. While 
this was observed in limited cases in our study, it was not a predefined SAP parameter under 
investigation; thus was omitted in adherence evaluation. As long as one dose of SAP was 
administered within 60 minutes before skin incision, the ‘timing’ component was considered 
‘adherent’; even if that dose was not the real first dose of SAP. In addition, only the duration 
parameter was evaluated in the post-op SAP regimen, but not the dose used. A proportion of 
post-op SAP was given as 1g thrice daily up to 24 hours, which had a lower dose than the 2g 
suggested by the in-hospital guideline. However, since the dosing post-op was not a 
predefined parameter, it was also omitted from our evaluation. The clinical effects of these 
two prescribing non-adherences are yet to be established. Future studies should try to include 
more detailed aspects when investigating adherence rates to SAP.  
 
4.2.5 External validity 
 
SVH is a large tertiary metropolitan hospital and has an established culture in 
following the Australian TG in practice. This can be reflected by the results in Phase 1 of this 
study. Thus the ability of this project to extrapolate the results to other smaller and rural 
hospitals may be in doubt.  
 
It may not be realistic for other smaller hospitals to develop their own in-hospital 
guidelines tailored for their practices as this is influenced by team culture, clinician education 
and practice experience. However, there is an opportunity for tertiary hospital AMS teams to 
support smaller hospitals to develop localised AMS resources and strategies such as DUE.  
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CHAPTER 5: CONCLUSIONS 
 
Our pre-post intervention study has demonstrated the efficacy of developing and 
distributing in-hospital guidelines, as well as face-to-face performance feedback with 
prescribers in improving adherence to surgical antibiotic prophylaxis guidelines.  
 
Adherence rates increased significantly in terms of drug option, dosing, timing and 
overall performance; while the adherence to duration parameter may be sophisticated due to 
other objective factors. Prescribers who have intermediate adherence to guidelines and 
relatively junior physicians were more likely to change their prescribing habits after 
appropriate interventions.  
 
Although not without flaws, our study has suggested successful measures to increase 
guideline adherence in other practice settings.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 Page 51  
REFERENCES 
                                                 
1 Kanji S. Antimicrobial prophylaxis in surgery. In: Dipiro J, Talbert R, Yee G, Matzke G, 
Wells B, Posey M, editors. Pharmacotherapy: A pathophysiological approach. 9th ed. United 
States of America. McGraw-Hill Education; 2014. 
2 Centres for Disease Control and Prevention (CDC). Surgical site infection (SSI) event 
[Internet]. 2016 [cited 2016 Sep 1]. Available from: 
http://www.cdc.gov/nhsn/PDFs/pscmanual/9pscssicurrent.pdf 
3 Rafati M, Shiva A, Ahmadi A, Habibi O. Adherence to American Society of Health-System 
Pharmacists surgical antibiotic prophylaxis guidelines in a teaching hospital. J Res Pharm 
Pract 2014;3:62-6. 
4 Gagliardi A, Fenech D, Eskicioglu C, Nathens A, McLeod R. Factors influencing antibiotic 
prophylaxis for surgical site infection prevention in general surgery: a review of the literature. 
Can J Surg. 2009;52:481-9.  
5 Burke J. Infection control – a problem for patient safety. N Engl J Med 2003;348:651-6. 
6 Kirkland K, Briggs J, Trivette S, Wilkinson W, Sexton D. The impact of surgical-site 
infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. 
Infect Control Hosp Epidermiol 1999;20:725-30. 
7 Perencevich E, Sands K, Cosgrove S, Guadagnoli E, Meara E et al. Health and economic 
impact of surgical site infections diagnosed after hospital discharge. Emerg Infect Dis 
2003;9:196-203. 
8 Safe care campaign. Surgical site infection [Internet]. 2007 [updated 2016; cited 2016 Sep 
1]. Available from: http://www.safecarecampaign.org/ssi.html 
9 Surgical prophylaxis [revised 2015]. In: eTG complete [Internet]. Melbourne: Therapeutic 
Guidelines Limited; 2016. 
10 Prospero E, Barbadoro P, Marigliano A, Martini E, D’errico M. Perioperative antibiotic 
prophylaxis: improved compliance and impact on infection rates. Epidemiol Infect 
2011;139:1326-31. 
11 Gillespie W, Walenkamp G. Antibiotic prophylaxis for surgery for proximal femoral and 
other closed long bone fractures. Cochrane Database Syst Rev 2010;3:CD000244. 
12 Prokuski L. Prophylactic antibiotics in orthopaedic surgery. J Am Acad Orthop Surg 
2008;16:283-93. 
13 Al-Azzam S, Alzoubi K, Mhaidat N, Haddadin R, Masadeh M, Tumah H et al. Preoperative 
antibiotic prophylaxis practice and guideline adherence in Jordan: a multi-centre study in 
Jordanian hospitals. J Infect Dev Ctries 2012;6:715-20. 
14 Choi W, Song J, Hwang J, Kim N, Cheong H. Appropriateness of antibiotic prophylaxis for 
major surgery in Korea. Infect Control Hosp Epidemiol 2007;28:997-1002. 
15 Lundine K, Nelson S, Buckley R, Putnis S, Duffy P. Adherence to perioperative antibiotic 
prophylaxis among orthopaedic trauma patients. Can J Surg 2010;53:367-72. 
16 Bratzler D, Dellinger E, Oslen K, Perl T, Auwaerter P, Bolon M et al. Clinical practice 
guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013;70:195-
283.  
17 Ng R, Chong C. Surgeons’ adherence to guidelines for surgical antimicrobial prophylaxis – 
a review. Am Med J 2012;5:534-40. 
18 Munckhof W. Antibiotics for surgical prophylaxis. Aust Prescr 2005;28:38-40. 
19 Evans R and AAOS Patients Safety Committee. Surgical site infection prevention and 
control: An emerging paradigm. J Bone Joint Surg Am 2009;91:2-9. 
20 Ou Y, Jing B, Guo F, Zhao L, Xie Q, Fang Y et al. Audits of the quality of perioperative 
antibiotic prophylaxis in ShanDong province, China, 2006 to 2011. Am J Infect Control 
   
 Page 52  
                                                                                                                                                       
2014;42:516-20. 
21 Mahdaviazad H, Masoompour S, Askarian M. Iranian surgeons’ compliance with the 
American Society of Health-System Pharmacists guidelines: Antibiotic prophylaxis in private 
versus teaching hospitals in Shiraz, Iran. J Infect Public Health 2011;4:253-9. 
22 Napolitano F, Izzo M, Giuseppe G, Angelillo I. Evaluation of the appropriate perioperative 
antibiotic prophylaxis in Italy. PLoS One 2013;8:e79532. 
23 Van Kasteren M, Kullberg B, De Boer A, Groot J, Gyssens I. Adherence to local hospital 
guidelines for surgical antimicrobial prophylaxis: a multicentre audit in Dutch hospitals. J 
Antimicrob Chemother 2003;51:1389-96. 
24 National antimicrobial prescribing survey [Internet] 2014 [cited 2015 Mar]. Available from: 
https://www.naps.org.au/Default.aspx 
25 Hohmann C, Eickhoff C, Radziwill R, Schulz M. Adherence to guidelines for antibiotic 
prophylaxis in surgery patients in German hospitals: a multicentre evaluation involving 
pharmacy interns. Infection 2012;40:131-7. 
26 Hawkins R, Levy S, Senter C, Zhao J, Doody K, Kao L et al. Beyond surgical care 
improvement program compliance: antibiotic prophylaxis implementation gaps. Am J Surg 
2013;206:451-6. 
27 Forbes S, Stephen W, Harper W, Loeb M, Smith R, Christoffersen E, McLean R. 
Implementation of evidence-based practices for surgical site infection prophylaxis: Results of 
a pre- and post-intervention study. J Am Coll Surg 2008;207:336-41. 
28 Levy S, Phatak U, Tsao K, Wray C, Millas S, Lally K et al. What is the quality of reporting 
studies of interventions to increase compliance with antibiotic prophylaxis? J Am Coll Surg 
2013;217:770-9. 
29 Alonso F, Scott A, Stika L, Westerholm B. Health authorities and drug utilization studies. 
In: Dukes M. Drug utilization studies – methods and uses [internet]. Copenhagen; World 
Health Organization 1993. [cited 2016 Oct 6]. Available from: 
http://apps.who.int/medicinedocs/documents/s21868en/s21868en.pdf 
30 American Society of Health-System Pharmacists. ASHP guidelines on medication use 
evaluation. Am J Health-Syst Pharm 1996;53:1953-5. 
31 Oh A, Goh L, Azim N, Tee C, Phung C. Antibiotic usage in surgical prophylaxis: a 
prospective surveillance of surgical wards at a tertiary hospital in Malaysia. J Infect Dev 
Ctries 2014;8:193-201. 
32 Miliani K, L’Heriteau F, Astagneau P. Non-compliance with recommendations for the 
practice of antibiotic prophylaxis and risk of surgical site infection: results of a multilevel 
analysis from the INCISO surveillance network. J Antimicrob Chemother 2009;64:1307-15. 
33 Musmar S, Baba H, Owais A. Adherence to guidelines of antibiotic prophylactic use in 
surgery: a prospective cohort study in North West Bank, Palestine. BMC Surg 2014;14:69. 
34 Antibiotic Expert Groups. Therapeutic Guidelines: Antibiotic. Version 14. Melbourne: 
Therapeutic Guidelines Limited; 2014. 
35 Hsu C, Cheng S. Practice guideline adherence and health care outcomes – use of 
prophylactic antibiotics during surgery in Taiwan. J Eval Clin Pract 2009;15:1091-6. 
36 Disseldorp J, Slingenberg E, Matute A, Delgado E, Hoepelman I. Application of guidelines 
on preoperative antibiotic prophylaxis in Leon, Nicaragua. Neth J Med 2006;64:411-6. 
37 McHugh M. The Chi-Square test of independence. Biochem Med 2013;23:143-9. 
38 Harper M. Biostatistics for the clinician. Pharmacotherapy self-assessment program. 4th ed. 
[Internet]. Cited 2016 Sep. Available from: 
http://www.vhpharmsci.com/decisionmaking/Therapeutic_Decision_Making/Fundamentals_f
iles/Biostatistics%20for%20the%20Clinician%20PSAP-4th%20Ed.pdf 
39 Pezzullo J. 2-way contingency table analysis [Internet]. 2013 [cited 2016 Sep]. Available 
   
 Page 53  
                                                                                                                                                       
from: http://statpages.info/ctab2x2.html 
40 ACT government. The art of feedback: giving, seeking and receiving feedback [Internet]. 
[Updated 2016 Feb 9; cited 2016 Sep 1]. Available from: 
http://www.cmd.act.gov.au/__data/assets/pdf_file/0003/463728/art_feedback.pdf 
41 Blanchard K, Johnson S. The new one minute manager. London: The Thorsons Classics; 
2015. 
42 Salkind A, Rao K. Antibiotic prophylaxis to prevent surgical site infections. Aust Fam 
Physician 2011;83:585-90. 
43 Haydon T, Presneill J, Robertson M. Antibiotic prophylaxis for cardiac surgery in Australia. 
Med J Aust 2010;192:141-3. 
44 Abdel-Aziz A, El-Menyar A, Al-Thani H, Zarour A, Parchani A, Asim M et al. Adherence 
of surgeons to antimicrobial prophylaxis guidelines in a tertiary general hospital in a rapidly 
developing country. Adv Pharmacol Sci 2014;3:62-7. 
45 Rossi S (editor), Australian Medicines Handbook 2016 (online). Adelaide: Australian 
Medicines Handbook Pty Ltd; 2016 Jan. Available from: http://www.amh.net.au 
46 Alexiou V, Lerodiakonou V, Peppas G, Falagas M. Antimicrobial prophylaxis in surgery: 
An international survey. Surg Infect 2010;11:343-8. 
47 Bailly P, Lallemand S, Thouverez M, Talon D. Multicentre study on the appropriateness of 
surgical antibiotic prophylaxis. J Hosp Infect 2001;49:135-8. 
48 Fukatsu K, Saito H, Matsuda T, Ikeda S, Furukawa S, Muto T. Influences of type and 
duration of antimicrobial prophylaxis on an outbreak of Methicillin-resistant Staphylococcus 
aureus and on the incidence of wound infection. Arch Surg 1997;132:1320-5. 
49 Elliott R, Weatherly H, Hawkins N, Cranny G, Chambers D, Myers L et al. An economic 
model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide 
antibiotic prophylaxis? Eur J Health Econ 2010;11:57-66. 
50 Archer G. Alteration of cutaneous Staphylococcal flora as a consequence of antimicrobial 
prophylaxis. Rev Infect Dis 1991;13:s805-9. 
51 Hansen E, Belden K, Silibovsky R, Vogt M. Perioperative antibiotics. J Orthop Res 
2014;32:s31-59. 
52 Scarlato R, Dowsey M, Buising K, Choong P, Peel T. What is the role of catheter antibiotic 
prophylaxis for patients undergoing joint arthroplasty? ANZ J Surg doi:10.1111/ans.13584 
53 Bond S, Boutlis C, Jansen S, Miyakis S. Discontinuation of peri-operative gentamicin use 
for indwelling urinary catheter manipulation in orthopaedic surgery. ANZ J Surg 3 June 2016 
doi: 10.1111/ans.13642 
54 Meehan J, Jamali A, Nguyen H. Prophylactic antibiotics in hip and knee arthroplasty. J 
Bone Joint Surg Am 2009;91:2480-90. 
55 Amyes S. Antimicrobial chemotherapy. Oxford: Oxford University Press;2010. 
56 Australian Bureau of Statistics. Profiles of health – height and weight [Internet]. Updated 
2013; cited 2016 Aug. Available from: 
http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4338.0main+features212011-13 
57 Preventing surgical site infections. [Internet] 2015 May [cited 2016 Sep 1]. Available from: 
http://www.patientsafetyinstitute.ca/en/toolsResources/Weight-Based-Dosing-Summary-
SSI/Documents/Weight-Based%20Dosing%20Summary_Physician%20Support%20Tool.pdf 
58 Ho V, Nicolau D, Dakin G, Pomp A, Rich B, Towe C et al. Cephazolin dosing for surgical 
prophylaxis in morbidly obese patients. Surg Infect 2012;13:33-7. 
59 Forse R, Karam B, MacLean D, Christou N. Antibiotic prophylaxis for surgery in morbidly 
obese patients. Surgery 1989;106:750-6. 
60 White A, Schneider T. Improving compliance with prophylactic antibiotic administration 
guidelines. AORN J 2007;85:173-80. 
   
 Page 54  
                                                                                                                                                       
61 Burke J. The effective period of preventive antibiotic action in experimental incisions and 
dermal lesions. Surgery 1961;50:161-8. 
62 Classen D, Evans S, Pestotnik S, Horn S, Menlove R, Burke J. The timing of prophylactic 
administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 
1992;326:281-6. 
63 Van Kasteren M, Mannien J, Ott A, Kullberg B, De Boer A, Gyssens I. Antibiotic 
prophylaxis and the risk of surgical site infections following total hip arthroplasty: timely 
administration is the most important factor. Clin Infect Dis 2007;44:921-7. 
64 Hawn M, Richman J, Vick C, Deierhoi R, Graham L, Henderson W et al. Timing of 
surgical antibiotic prophylaxis and the risk of surgical site infection. JAMA Surg 
2013;148:649-57. 
65 Weber W, Marti W, Zwahlen M, Misteli H, Rosenthal R, Reck S et al. The timing of 
surgical antibiotic prophylaxis. Ann Surg 2008;247:918-26. 
66 Steinberg J, Braun B, Hellinger W, Kusek L, Bozikis M, Bush A et al. Timing of 
antimicrobial prophylaxis and the risk of surgical site infections. Ann Surg 2009;250:10-6. 
67 Bratzler D, Houck P. Antimicrobial prophylaxis for surgery: An advisory statement from 
the National surgical infection prevention project. Clin Infect Dis 2004;38:1706-15. 
68 Morrison S, White N, Asadollahi S, Lade J. Single versus multiple doses of antibiotic 
prophylaxis in limb fracture surgery. ANZ J Surg 2012;82:902-7. 
69 Nelson C, Green T, Poter R, Warren R. One day versus seven days of preventative 
antibiotic therapy in orthopaedic surgery. Clin Orthop Relat Res 1983;176:258-63. 
70 Terpstra S, Noordhoek G, Voesten H, Hendriks B, Degener J. Rapid emergence of resistant 
coagulase-negative staphylococci on the skin after antibiotic prophylaxis. J Hosp Infect 
1999;43:195-202. 
71 Imai-Kamata S, Fushimi K. Factors associated with adherence to prophylactic antibiotic 
therapy for elective general surgeries in Japan. Int J Qual Health Care 2011;23:167-72. 
72 Goede W, Lovely J, Thompson R, Cima R. Assessment of prophylactic antibiotic use in 
patients with surgical site infections. Hosp Pharm 2013;48:560-7. 
73 Trampuz A, Zimmerli W. Antimicrobial agents in orthopaedic surgery: prophylaxis and 
treatment. Drugs 2006;66:1089-105. 
74 Lidgren L, Knutson K, Stefansdottir A. Infection of prosthetic joints. Best Pract Res Clin 
Rheumatol 2003;17:209-18. 
75 Bornmann L. The Hawthorne effect in journal peer review. Scientometrics 2012;91:857-62. 
76 Dimitrov D, Rumrill P. Pretest-posttest designs and measurement of change. Work 
2003;20:159-65. 
77 Kowalczyk D. Quasi-experimental designs: Definitions, characteristics, types & examples 
[Internet]. Cited 2016 Aug 26. Available from: http://study.com/academy/lesson/quasi-
experimental-designs-definition-characteristics-types-examples.html 
78 Kao L, Lew D, Doyle P, Carrick M, Jordan V, Thomas E et al. A tale of 2 hospitals: a 
staggered cohort study of targeted interventions to improve compliance with antibiotic 
prophylaxis guidelines. Surgery 2010;148:255-62. 
79 Osowlckl J, Gwee A, Noronha J, Palasanthlran P, McMullan B, Britton P et al. Australia-
wide point prevalence survey of the use and appropriateness of antimicrobial prescribing for 
children in hospital. Med J Aust 2014;201:657-62. 
 
 
 
 
   
 Page 55  
                                                                                                                                                       
APPENDICES 
 
Appendix 1 – Drug Use Evaluation instrument 
Category Details Patient 1 Patient 2 etc 
Patient parameters Participant code   
Age   
Sex  Male 
 Female 
 
Allergy status  Penicillin (Anaphylactic) 
 Penicillin (Rash) 
 Cefalosporin 
 Others:________________ 
 
Weight (kg)   
Height (cm)   
Renal function (mL/min)   
ASA score  1. Normal healthy 
 2. Mild systemic 
 3. Severe systemic 
 4. Systemic threat to life 
 5. Expected survival <24hrs 
 
Doctor parameters Name   
Rank in team  Consultant/Chief of service 
 Registrar 
 Resident 
 Intern 
 
Surgery parameters Date performed &  
Date of admission 
  
Type of surgery  Hip replacement 
 Knee replacement 
 ORIF 
 
Type of wound  Clean 
 Clean-contaminated 
 Contaminated 
 Dirty 
 Unknown 
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In-opt time, out-op time, 
Induction time, 
Incision time 
  
Drug parameters Agent 
(Use numbers instead of 
tick if >1 agent; include 
‘prophylaxis’ started after 
surgery ) 
 Cefazolin 
 Flucloxacillin 
 Vancomycin 
 Unknown 
 Others: ________________ 
 None 
 
If Vancomycin, reason?  P/C allergy 
 MRSA 
 Prolonged hospital stay 
 Not specified 
 Others: ________________ 
 
If other agents, reason?   
Dose of each agent   
Time of administration  
exc vanc 
(Use numbers instead of 
tick if >1 agent) 
  
Vanc time of admin   
Date & Time of  
last dose of SAP 
  
Overall comment on 
appropriateness 
Drug choice  Yes 
 No 
 
Reasons: 
 
 
Dose  Yes 
 No 
 
Reasons: 
 
 
Timing   Yes 
 No 
 
Reasons: 
 
 
Duration   Yes 
 No 
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Reasons: 
 
 
All aspects   Yes 
 No 
 
Reasons: 
 
 
 
 
 
Appendix 2 – Terms and procedure codes for patients list retrieval 
Type of surgery Procedure name/code 
Hip replacement Hip replacement 
Total Arthroplasty of hip 
Hemiarthroplasty of femur 
Knee replacement Knee replacement 
Total arthroplasty of knee 
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Open reduction with  
internal fixation 
(ORIF) 
Implantation of prosthetic device of arm 
Implantation of prosthetic device of leg 
Osteotomy of humerus with internal fixation 
Open reduction of fracture of proximal humerus with internal 
fixation 
Open reduction of intra-articular fracture of proximal humerus with 
internal fixation 
Open reduction of fracture of shaft of humerus with internal fixation 
Open reduction of fracture of distal humerus with internal fixation 
Bone graft to humerus with internal fixation 
Osteotomy of radius with internal fixation 
Osteotomy of ulna with internal fixation 
Open reduction of fracture of radial head or neck with internal 
fixation 
Open reduction of fracture of shaft of radius with internal fixation 
Open reduction of fracture of distal radius with internal fixation 
Open reduction of fracture of olecranon with internal fixation 
Open reduction of fracture of olecranon with partial ostectomy of 
olecranon fragment and internal fixation 
Open reduction of fracture of shaft of ulna with internal fixation 
Open reduction of fracture of distal ulna with internal fixation 
Open reduction of fracture of shaft of radius and ulna with internal 
fixation 
Open reduction of fracture of shaft of radius with dislocation and 
internal fixation 
Open reduction of fracture of shaft of ulna with dislocation and 
internal fixation 
Open reduction of dislocation of distal radio-ulnar joint with 
internal fixation 
Bone graft to radius or ulna with internal fixation 
Bone graft to radius and ulna with internal fixation 
Osteotomy of proximal femur with internal fixation 
Osteotomy of mid femur with internal fixation 
Internal fixation of fracture of trochanteric or subcapital femur 
Open reduction of fracture of femur with internal fixation 
Osteotomy of distal femur with internal fixation 
Osteotomy of tibia with internal fixation 
Osteotomy of fibula with internal fixation 
Open reduction of fracture of medial or lateral tibial plateau with 
internal fixation 
Open reduction of fracture of medial and lateral tibial plateau with 
internal fixation 
Open reduction of fracture of shaft of tibia with internal fixation 
Open reduction of intra-articular fracture of shaft of tibia with 
internal fixation 
Open reduction of fracture of fibula with internal fixation 
Transfer of fibula to tibia with internal fixation 
Internal fixation of fracture of femur or tibia with reconstruction 
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Appendix 3 –  Sources of data to complete DUE instrument 
Data Sources 
Patient name, MRN, name of procedure Coding file from Medical Records office; 
Anaesthetic & Recovery record; 
Operating room registered nurses report 
 
Patient’s sex, age Anaesthetic & Recovery record; 
Patient identity label 
 
Allergy status Anaesthetic & Recovery record; 
Pre-operative checklist 
 
Weight, Height Anaesthetic & Recovery record; 
SVH WebdeLacy patient waterlow pressure 
injury assessment; 
Patient health questionnaire 
 
Renal function SVH WebdeLacy general pathology report 
ASA Operating room registered nurses report 
Wound class Operation record form 
Operation Summary Operation record form 
Physician Coding file from Medical Records office; 
Operating room registered nurses report 
 
Proposed & Actual date of surgery Anaesthetic & Recovery record 
Admission date Coding file from Medical Records office; 
Patient progress notes 
 
Time of surgery (In & Out theatre time) Operating room registered nurses report 
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Induction time Operating room registered nurses report; 
Anaesthetic & Recovery record 
 
Incision time Surgical safety checklist –  
team time out before skin incision form 
 
Necessity of SAP (whether SAP is indicated) Surgical safety checklist –  
team time out before skin incision form 
 
Antibiotic agent, dose &  
administration time (first & in-surgery dose) 
 
Anaesthetic & Recovery record 
Microbiology status (including MRSA) SVH WebdeLacy microbiology report 
Post-op plan for antibiotics Operation record form –  
post operative instructions 
 
Time of administration post-op doses Medchart –  
medicines prescribing and administration 
record 
 
Admission record in past 3 months Medchart 
SVH WebdeLacy 
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Appendix 4 – SVH In-hospital guidelines developed by AMS, distributed in Phase 2 
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Appendix 5 – Abbreviations used 
Abbreviations Explanations 
 
AAOS American Academy of Orthopaedic surgeons 
AMS Antimicrobial Stewardship 
ASHP American Society of Health-System 
pharmacists 
DUE Drug-use evaluation 
ICU Intensive care unit 
MIC Minimum inhibitory concentration 
MRSA Multi-drug resistant Staphylococcus aureus 
NAPS  National Antimicrobial Prescribing survey 
ORIF Open reduction with internal fixation 
SAP Surgical antibiotic prophylaxis 
SIGN Scottish Intercollegiate Guidelines Network 
SOP, UQ School of Pharmacy, University of 
Queensland 
SSIs Surgical site infections 
SVH St. Vincent’s Public Hospital, Sydney 
TG Therapeutic Guidelines 
 
